Distribution of Ki67 Proliferative Indices among WHO Subtypes of Non-Hodgkin's Lymphoma: Association with other Clinical Parameters |
Hashmi, Atif Ali
(Department of Histopathology, Liaquat National Hospital and Medical College)
Hussain, Zubaida Fida (Department of Histopathology, Liaquat National Hospital and Medical College) Faridi, Naveen (Department of Histopathology, Liaquat National Hospital and Medical College) Khurshid, Amna (Department of Histopathology, Liaquat National Hospital and Medical College) |
1 | Salek D, Vesela P, Boudova L et al (2014). Retrospective analysis of 235 unselected patients with mantle cell lymphoma confirms prognostic relevance of Mantle Cell Lymphoma International Prognostic Index and Ki-67 in the era of rituximab: long-term data from the Czech Lymphoma Project Database. Leuk Lymphoma, 55, 802-10. DOI |
2 | Petit B, Chaury MP, Le Clorennec C et al (2005).Indolent lymphoplasmacytic and marginal zone B-cell lymphomas: absence of both IRF4 and Ki67 expressionidentifies a better prognosis subgroup. Haematologica, 90, 200-6. |
3 | Pinto AE, Cabecadas J, Nobrega SD, Mendonca E (2003). Flow cytometric S-phase fraction as a complementary biological parameter for the cytological grading of non-Hodgkin's lymphoma. Diagn Cytopathol, 29, 194-9. DOI |
4 | Rabenhorst SH, Burini RC, Schmitt FC (1996). Proliferating cell nuclear antigen (PCNA) in non-Hodgkin's lymphomas: correlation with Working Formulation and Kiel classification in formalin-fixed paraffin-embedded material. Pathology, 28, 12-16. DOI |
5 | Rosenwald A, Wright G, Wiestner A et al (2003). The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survivalin mantle cell lymphoma. Cancer Cell, 3, 185-97. DOI ScienceOn |
6 | Zekri AR, Hassan ZK, Bahnassy AA et al (2013). Gene expression profiling of non-hodgkin lymphomas. Asian Pac J Cancer Prev, 14, 4393-8. 과학기술학회마을 DOI |
7 | Schaffel R, Hedvat CV, Teruya-Feldstein J et al (2010). Prognostic impact of proliferative index determined by quantitative image analysis and the InternationalPrognostic Index in patients with mantle cell lymphoma. Ann Oncol, 21, 133-9. DOI |
8 | Swerdlow SH, Camp E, Harris NL et al (2008). WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. In World Health Organization Classification of Tumors, 4th ed. Lyon: International Agency for Research. |
9 | Vaidya R, Witzig TE (2014). Prognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era. Ann Oncol. pii: mdu109. |
10 | Went P, Agostinelli C, Gallamini A, Piccaluga PP, Ascani S (2006). Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. J Clin Oncol, 24, 2472-9. DOI |
11 | Wu L, Wang T, Gui W, Lin H, Xie K (2014). Prognostic Significance of Serum Beta-2 Microglobulin in Patients with Non-Hodgkin Lymphoma. Oncology, 87, 40-47. DOI |
12 | Zhang ZX, Shen CF, Zou WH et al (2013). Exploration of molecular mechanisms of diffuse large B-cell lymphoma development using a microarray. Asian Pac J Cancer Prev, 14, 929-34. DOI |
13 | Zhou D, Xie WZ, Hu KY et al (2013). Prognostic values of various clinical factors and genetic subtypes for diffuse large B-cell lymphoma patients: a retrospective analysis of 227 cases. Asian Pac J Cancer Prev, 4, 929-34. 과학기술학회마을 DOI |
14 | Bellas C, Garcia D, Vicente Y et al (2014). Immunohistochemical and molecular characteristics with prognostic significance in diffuse large B-celllymphzoma. PLoS One, 9, e98169. DOI |
15 | Bhurgri Y, Pervez S, Bhurgri A et al (2005). Increasing incidence of non-Hodgkin's lymphoma in Karachi, 1995-2002. Asian Pac J Cancer Prev, 6, 364-9. |
16 | Broyde A, Boycov O, Strenov Y et al (2009). Role and prognostic significance of the Ki-67 index in non-Hodgkin's lymphoma. Am J Hematol, 84, 338-43. DOI ScienceOn |
17 | Broyde A, Boycov O, Strenov Y et al (2009). Role and prognostic significance of the Ki-67 index in non-Hodgkin's lymphoma. Am J Hematol, 84, 338-43. DOI ScienceOn |
18 | Erlanson M, Casiano CA, Tan EM et al (1999). Immunohistochemical analysis of the proliferation associated nuclear antigen CENP-F in non-Hodgkin's lymphoma. Mod Pathol, 12, 69-74. |
19 | Cook JR, Goldman B, Tubbs RR et al (2014). Clinical significance of MYC expression and/or “high-grade” morphology in non-Burkitt, diffuse aggressive B-cell lymphomas: a SWOG S9704 correlative study. Am J Surg Pathol, 38, 494-501. DOI |
20 | Gaudio F, Giordano A, Perrone T et al (2011). High Ki67 index and bulky disease remain significant adverse prognostic factors in patients with diffuse large B cell lymphoma before and after the introduction of rituximab. Acta Haematol, 126, 44-51. DOI |
21 | Akay OM, Aras BD, Isiksoy S et al (2014). BCL2, BCL6, IGH, TP53, and MYC protein expression and gene rearrangements as prognostic markers in diffuse large B-cell lymphoma: a study of 44 Turkish patients. Cancer Genet, 207, 87-93. DOI |
22 | Ali AE, Morgen EK, Geddie WR et al (2010). Classifying B-cell non-Hodgkin lymphoma by using MIB-1 proliferative index in fine-needle aspirates. Cancer Cytopathol, 118, 166-72. DOI |
23 | Gerdes J, Lemke H, Baisch H et al (1984). Cell cycle analysis of a cell proliferation- associated human nuclear antigen defined by monoclonal antibody Ki67. J Immunol, 133, 1710-1715 |
24 | Gerdes J, Schwab U, Lemke H, Stein H (1983). Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer, 31, 13-20 DOI |
25 | Gunia S, Kakies C, Erbersdobler A, Koch S, May M (2012). Scoring the percentage of Ki67 positive nuclei is superior to mitotic count and the mitosis marker phosphohistone H3 (PHH3) in terms of differentiating flat lesions of the bladder mucosa. J Clin Pathol, 65, 715-20. DOI |
26 | He X, Chen Z, Fu T et al (2014). Ki-67 is a valuable prognostic predictor of lymphoma but its utility varies in lymphoma subtypes: evidence from a systematic meta-analysis. BMC Cancer, 14, 153. DOI |
27 | Hadzi-Pecova L, Petrusevska G, Stojanovic A (2007). Non-Hodgkin's lymphomas: immunologic prognostic studies. Prilozi, 28, 39-55. |
28 | Haroon S, Hashmi AA, Khurshid A et al (2013). Ki67 index in breast cancer: correlation with other prognostic markers and potential in Pakistani patients. Asian Pac J Cancer Prev, 14, 4353-8. 과학기술학회마을 DOI |
29 | Jung SH, Yang DH, Ahn JS et al (2014). Serum lactate dehydrogenase with a systemic inflammation score is useful for predicting response and survival in patients with newly diagnosed diffuse large b-cell lymphoma. Acta Haematol, 133, 10-17. |
30 | Ishtiaq S, Hassan U, Mushtaq S, Akhtar N (2013). Determination of frequency of Epstein-Barr virus in non-Hodgkin lymphomas using EBV latent membrane protein 1 (EBVLMP1) immunohistochemical staining. Asian Pac J Cancer Prev, 14, 3963-7. 과학기술학회마을 DOI |
31 | Jerkeman M, Anderson H, Dictor M, Kvaloy S, Akerman M (2004). Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma--a Nordic Lymphoma Group study. Ann Hematol, 83, 414-9. DOI ScienceOn |
32 | Kalogeraki A, Tzardi M, Panagiotides I et al (1997). MIB1 (Ki-67) expression in non-Hodgkin's lymphomas. Anticancer Res, 17, 487-491. |
33 | Li J, Hu R, Liao AJ et al (2011). Ki-67 proliferative index in non-Hodgkin's lymphoma and its clinical significance. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 19, 935-9. |
34 | Niikura N, Iwamoto T, Masuda S et al (2012). Immunohistochemical Ki67 labeling index has similar proliferation predictive power to various gene signatures in breast cancer. Cancer Sci, 103, 1508-12. DOI |
35 | Li S, Feng X, Li T et al (2013). Extranodal NK/T-cell lymphoma, nasal type: a report of 73 cases at MD Anderson Cancer Center. Am J Surg Pathol, 14, 14-23. |
36 | Martin AR, Weisenburger DD, Chan WC et al (1995). Prognostic value of cellular proliferation and histologic grade in follicular lymphoma. Blood, 85, 3671-8. |